FDA Updates Draft Guidance on Drug Cost Talks
Published Date: 6/3/2026
Notice
Summary
The FDA just released a revised draft guide to help drug and device makers share important cost and coverage info with insurance companies and similar groups. This update clears up how to talk about approved products, unapproved products, and new uses, making it easier for everyone to understand the rules. Companies should send their feedback by August 3, 2026, so the FDA can finalize the guide—potentially speeding up coverage decisions and saving money.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Paperwork Burden: 210,561 Annual Hours
FDA estimates the revised guidance’s recommended disclosures will result in 12,960 total annual disclosures and 210,561 total annual burden hours across firms. Examples in FDA’s estimate: about 600 manufacturers producing 7,800 HCEI materials for approved prescription drugs (20 hours each); about 260 manufacturers producing 2,600 HCEI materials for approved/cleared devices (20 hours each); unapproved-product communications and follow-ups use 0.5 hours and 2 hours per disclosure respectively. FDA also reports an overall increase of 7,883 hours and 472 disclosures in its estimate.
Safe Harbor for HCEI on Approved Products
If you are a drug or device manufacturer, FDA’s revised draft guidance says health care economic information (HCEI) you give to payors about FDA-approved or cleared products will not be considered false or misleading if it (1) relates to an FDA-approved indication, (2) is based on competent and reliable scientific evidence, and (3) includes, when applicable, a conspicuous statement describing material differences from FDA-approved labeling. This is a revised draft guidance that, when finalized, will replace the June 2018 guidance.
Safe Harbor for Unapproved Product Information
If you are a drug or device manufacturer, FDA’s revised draft guidance explains that under section 502(gg) certain truthful and not-misleading communications to payors about investigational or unapproved medical products or investigational uses of approved/cleared products will not cause the product to be treated as misbranded under section 502(f)(1). The guidance states such communications must meet the statutory criteria in section 502(gg) (e.g., be the type of product information defined in 502(gg)(2) and be presented with the information set forth in 502(gg)(1)(A)).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11062 — Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
The FDA is officially pulling the plug on 16 generic drug approvals because the companies told them these medicines aren’t being sold anymore. This change kicks in on July 6, 2026, and it won’t stop companies from trying again later if they want. If you’re a drug maker or just curious, this means fewer old approvals cluttering the books and a cleaner, fresher drug list.
2026-11101 — Third Annual Animal Drug User Fee Educational Conference; Public Meeting
The FDA is hosting its Third Annual Animal Drug User Fee Educational Conference on July 7, 2026, to help drug makers and animal health experts understand the new animal drug approval process. This free event is both in-person and online, making it easy to join. Stakeholders should register early and can send feedback within 90 days after the meeting to help shape future policies and fees.
2026-11054 — Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help companies making gene therapy products that use genome editing. It shows how to use what’s already known to speed up development and get safer, smarter treatments to patients faster. If you’re in this field, send your feedback by September 1, 2026, so your voice shapes the final rules—saving time and money down the road!
2026-10904 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Orally Ingested Transient Device for Constipation
The FDA is officially putting the new swallowed device for constipation into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this cool innovation by cutting down red tape. The new rules took effect June 1, 2026, and could save companies time and money getting their devices approved.
2026-10908 — Medical Devices; General Hospital and Personal Use Devices; Classification of the Rigid Sterilization Container With Electronic Monitoring
The FDA is officially classifying rigid sterilization containers with electronic monitoring as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change helps hospitals and medical device makers get these safer, smarter containers to patients faster and easier. The new rules took effect June 1, 2026, making it simpler and potentially less costly to bring these devices to market.
2026-10873 — Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products; Draft Guidance for Industry; Availability
The FDA is rolling out a new draft guide to help cancer drug makers speed up safety testing for biologic and conjugated medicines. This plan cuts down on extra animal testing and uses smarter methods learned during the COVID-19 pandemic. Drug developers should send their feedback by July 31, 2026, to shape the final rules and save time and money in bringing new cancer treatments to patients.
Previous / Next Documents
Previous: 2026-11059 — Parts and Accessories Necessary for Safe Operation; Application for Exemption From Truck-Lite Co. LLC
Truck-Lite Co. LLC got the green light to let trucks use special flashing amber brake lights along with the regular steady ones for the next five years. This change aims to keep trucks just as safe, if not safer, on the road. Truck drivers and companies can start using these new lights from May 29, 2026, through June 3, 2031, with no extra costs announced.
Next: 2026-11062 — Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
The FDA is officially pulling the plug on 16 generic drug approvals because the companies told them these medicines aren’t being sold anymore. This change kicks in on July 6, 2026, and it won’t stop companies from trying again later if they want. If you’re a drug maker or just curious, this means fewer old approvals cluttering the books and a cleaner, fresher drug list.